Navigation Links
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
Date:7/2/2009

EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte. The report was published online in the early edition (June 29) of the Proceedings of the National Academy of Science (US). The print version will appear July 14.

Dr. John S. Kovach, President and CEO of Lixte, said "LB-1.2 exerts anti-cancer activity directly on the cancer cell and, more dramatically, by preventing cancer cells from recovering from DNA-damage produced by standard anti-cancer drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of children. Temozolomide, the standard drug for the treatment of patients with GBM, by itself caused regression but with recurrence of all tumors."

Dr. Kovach added "that, since LB-1.2 has a biochemical action similar to an older drug used for anticancer treatment for many years in China, we are cautiously optimistic that LB-1.2 will be well tolerated by cancer patients and hopefully, will potentially be as effective as it is in animal models of human cancer. We believe that adding LB-1.2 may be a general method for improving the effectiveness of several standard anticancer drugs not only against tumors of the brain and neural tissue but also against other cancers sensitive to drugs that work by damaging DNA. Safe
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
7. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
8. Yongye Biotechnology International Receives License to Manufacture Products
9. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
10. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... Stage Product Targeting Life-threatening Hereditary ... to Host Conference Call at 10:30 A.M. Eastern Today to Discuss ... ... Incorporated,(Nasdaq: VPHM ) and Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP),today ...
... July 15 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin ... firm specializing in the manufacture,research, development, marketing ... appointment of American Stock Transfer & Trust ... registrar, effective August 15, 2008.,AST, headquartered in ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... results will be released on,Thursday, July 31, 2008. The ... 10:00 a.m. Eastern Time, July 31, 2008, to discuss ... by Steven G.,Anderson, president and CEO of CryoLife, Inc., ...
Cached Biology Technology:ViroPharma To Acquire Lev Pharmaceuticals 2ViroPharma To Acquire Lev Pharmaceuticals 3ViroPharma To Acquire Lev Pharmaceuticals 4ViroPharma To Acquire Lev Pharmaceuticals 5ViroPharma To Acquire Lev Pharmaceuticals 6ViroPharma To Acquire Lev Pharmaceuticals 7ViroPharma To Acquire Lev Pharmaceuticals 8ViroPharma To Acquire Lev Pharmaceuticals 9China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008 2CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:7/25/2014)... central nervous system disease that is caused by ... the embryonic phase. Many patients have varying degrees ... retardation. Such problems decrease the patients, functional independence ... Physical Medicine and Rehabilitation Education and Research Hospital, ... SB, using the Pediatric Evaluation of Disability Inventory ...
(Date:7/25/2014)... researchers have detected an unknown interaction between microorganisms and ... into a droplet of salt water and is left ... create biomineralogical biosaline 3D morphologically complex formations, where they ... revived. The discovery was made by chance with a ... Astrobiology journal and may help to find ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... Studies show the incidence of diabetes in dogs has increased ... Missouri veterinarians have changed the way veterinarians treat diabetes in ... humans. Dogs are susceptible to type 1, insulin-dependent diabetes. ... because their bodies do not produce enough insulin, a hormone ...
... around the world have forced many species to the brink ... multiple causes that are still not fully understood, researchers conclude ... causative factor is often missing the larger picture, they said, ... don,t consider the totality of causes or could even ...
... April 25, 2011 - Call them the Jason Bournes of ... secret agents, some bacteria avoid antibiotic treatments by essentially shutting ... says Thomas Wood, professor in the Artie McFerrin Department of ... elaborate survival mechanism is explained in the online April edition ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3